China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.

The Impact of China’s Policies on Global Biopharmaceutical Industry Innovation

ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.

Seizing the Transformative Opportunity of Multi-cancer Early Detection

Blood-based multi-cancer early detection (MCED) technologies hold the promise to revolutionize America’s cancer-screening paradigm, dramatically expanding the range of detectable cancers and identifying them at earlier stages when cancers are more treatable. Policymakers should provide a supportive regulatory and coverage environment.

America’s lead in life sciences is being challenged. Other countries are aggressively seeking to attract and grow companies with innovation-based tax incentives, a range of firm-specific enticements, increased government research funding, improved IP protections, and streamlined regulatory approval processes. The federal government should act to ensure U.S. life sciences remain competitive.

How to Ensure That America’s Life-Sciences Sector Remains Globally Competitive

Marking the release of a new report, ITIF hosted a discussion with experts and leaders from leading biopharmaceutical startups to discuss current challenges and opportunities, and what the federal government should and should not do to maintain this unique American strength.

The Critical Role of Biopharmaceutical Startups in Driving Life Sciences Innovation

Twenty-five case studies underscore how innovators in developing countries—often enabled by robust IP rights—are achieving advances in life sciences and healthcare that benefit people around the world.

Innovate4Health: How Innovators Are Solving Global Health Challenges

Please join ITIF to discuss a new report exploring why building out digital and hybrid infrastructure is critical to seizing the next wave of economic opportunities, creating jobs, and improving people’s quality of life.

Digitizing America’s Infrastructure for the 21st Century Economy

Life-sciences companies grow best in locations that can combine qualities like a good business environment, skilled workers, strong research universities, and available capital. Strengthening these and related factors can give states a stronger competitive advantage.

Growing the Future: State Efforts to Advance the Life Sciences

ITIF hosted a discussion on this critical issue. The event featured a keynote address by Simon Tripp of TEConomy Partners, author of the new report “Response and Resilience: Lessons Learned from Global Life Sciences Ecosystems in the COVID-19 Pandemic,” followed by an expert panel of respondents.

Lessons Learned From Global Life Sciences Ecosystems in the COVID-19 Pandemic

Documents the role public investment plays in underpinning a nation’s competitiveness in the life sciences and competition for global life sciences leadership. NIH Director Francis S. Collins endorses this report in a recent New York Times interview.

Leadership in Decline: Assessing U.S. International Competitiveness in Biomedical Research

On Wednesday, March 13, the House Ways and Means Trade Subcommittee held a hearing on the turbulent state of U.S.-India trade relations. The Subcommittee’s hearing reflects growing attention and concern related to India’s recent embrace of a wide slate of “innovation mercantilist” policies that seek to bolster Indian economic and employment growth by distorting global trade rules and forcing investment and production to occur in India. India has erected these policies in a diverse range of sectors from information and communications technology (ICT) to life sciences, clean energy, and retail. For instance, in February 2012, the Indian Ministry of Communications and Information Technology announced a Preferential Market Access mandate for electronic goods (the PMA Mandate) which imposes local content requirements on procurement of electronic products by government and private sector entities with “security implications for the country.” A specified share of each product’s market—anywhere from 30 to possibly even up to 100 percent—would have to be filled by India-based manufacturers, with the local content share for each product rising over time. The policy’s coverage is so broad it could easily capture half of India’s ICT market. In fact, on March 12, 2013, India’s Department of Telecommunications sought the Defense Ministry’s approval to classify select telecom products as “security sensitive” in the run-up to mandating 100 percent domestic sourcing for private sector gear procurements. 

The Indian Economy at a Crossroads

As Singapore continues its efforts to transform a small island nation into a global innovation hub, the innovation-enabling trade regime the Trans-Pacific Partnership fosters will benefit all industries but especially advanced technology ones, in areas such as life sciences and information technology, on which Singapore’s economy (like America’s) increasingly thrives, writes John Wu in Innovation Files.

How the Trans-Pacific Partnership Agreement Will Strengthen Singapore’s Innovation Economy (Like America’s)

The Budget Control Act would be a hard hit to federal R&D investments in life sciences, aerospace, defense and more, with significant long-term consequences to economic growth.

Eroding Our Foundation: Sequestration, R&D, Innovation and U.S. Economic Growth

The United States is the leader in life sciences innovation, but that has not always been the case. As global competition intensifies, it needs to continue spurring investment in R&D to stay on top. Rob and Jackie sat down with Stephen Ezell, vice president of global innovation policy at ITIF, to discuss the history of U.S. life sciences innovation and break down R&D costs versus the market prices of innovative biopharmaceuticals.

Podcast: R&D Costs, Rx Prices, and the Formula for Success in Life Sciences Innovation, With Stephen Ezell

Dogmatic opponents of life sciences innovation threaten to sue the Food and Drug Administrator for following the law to enable field trials of a new approach to (pesticide-free) mosquito-borne disease control, writes Val Giddings in Innovation Files.

Mosquito Madness

Stephen Ezell gave a presentation on “Seizing the Transformative Opportunity of Multi-cancer Early Detection” at the 15th Annual Next Generation Dx Summit.

Stephen Ezell gave a presentation on “Seizing the Transformative Opportunity of Multi-cancer Early Detection” at the 15th Annual Next Generation Dx Summit in Washington, DC on August 22, 2023.

Seizing the Transformative Opportunity of Multi-cancer Early Detection

Related Search Content

The Impact of China’s Policies on Global Biopharmaceutical Industry Innovation

Seizing the Transformative Opportunity of Multi-cancer Early Detection

Seizing the Transformative Opportunity of Multi-cancer Early Detection